Needham analyst Mike Matson downgraded Boston Scientific (BSX) to Hold from Buy without a price target The firm expects the company’s electrophysiology business to “slow significantly” in 2025 and cause its overall revenue growth to slow. Needham also sees risk around Boston Scientific’s ACURATE trial results. While investor expectations for ACURATE are low, the trial results are a catalyst that could move the shares up or down by 5%-10%, contends the firm. With the shares above its prior price target Needham views Boston Scientific as fairly valued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific downgraded to Hold from Buy at Needham
- Johnson & Johnson reported strong earnings beat, says Barclays
- Boston Scientific price target raised to $100 from $90 at Truist
- Boston Scientific price target raised to $93 from $84 at BTIG
- Boston Scientific price target raised to $95 from $85 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com